miR ‐21‐5p promotes NASH ‐related hepatocarcinogenesis
Liver International · 2023
DOI: 10.1111/liv.15682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2023. Verfasst von Pedro M Rodrigues und 19 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, Ikerbasque, Basque Foundation for Science, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background and Aims The mechanisms governing the progression of non‐alcoholic fatty liver disease (NAFLD) towards steatohepatitis (NASH) and hepatocellular carcinoma (HCC) remain elusive. Here, we evaluated the role of hsa‐miRNA‐21‐5p in NASH‐related hepatocarcinogenesis.
Methods
Hepatic hsa‐miR‐21‐5p expression was evaluated in two cohorts of patients with biopsy‐proven NAFLD ( n = 199) or HCC ( n = 366 HCC and n = 11 NAFLD‐HCC). Serum/liver metabolomic profiles were correlated with hsa‐miR‐21‐5p in NAFLD obese patients. Wild‐type (WT) and Mir21 KO mice were fed a choline‐deficient, amino acid‐defined (CDAA) diet for 32 and 66 weeks to induce NASH and NASH‐HCC, respectively.
Results
In obese individuals, hsa‐miR‐21‐5p expression increased with NAFLD severity and associated with a hepatic lipotoxic profile. CDAA‐fed WT mice displayed increased hepatic mmu‐miR‐21‐5p levels and progressively developed NASH and fibrosis, with livers presenting macroscopically discernible pre‐neoplastic nodules, hyperplastic foci and deregulated cancer‐related pathways. Mir21 KO mice exhibited peroxisome‐proliferator‐activated receptor α (PPARα) activation, augmented mitochondrial activity, reduced liver injury and NAS below the threshold for NASH diagnosis, with the pro‐inflammatory/fibrogenic milieu reversing to baseline levels. In parallel, Mir21 KO mice displayed reduced number of pre‐neoplastic nodules, hepatocyte proliferation and activation of oncogenic signalling, being protected from NASH‐associated carcinogenesis. The hsa‐miRNA‐21‐5p/PPARα pathway was similarly deregulated in patients with HCC‐ or NASH‐related HCC, correlating with HCC markers and worse prognosis.
Conclusions
Hsa‐miR‐21‐5p is a key inducer of whole‐spectrum NAFLD progression, from simple steatosis to NASH and NASH‐associated carcinogenesis. The inhibition of hsa‐miR‐21‐5p, leading to a pro‐metabolic profile, might constitute an appealing therapeutic approach to ameliorate NASH and prevent progression towards HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
- Centre for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.
- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
- Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- OWL Metabolomics, Derio, Spain.
ORCID-Profile: Pedro M Rodrigues, Marta B Afonso, André L Simão, Jesper B Andersen, Jesus M Banales, Cecília M P Rodrigues, Rui E Castro
Förderung
- Fundação para a Ciência e a Tecnologia
- Ikerbasque, Basque Foundation for Science
- Instituto de Salud Carlos III
- Osasun Saila, Eusko Jaurlaritzako
Zitieren
APA
Rodrigues, P. M., Afonso, M. B., Simão, A. L., Islam, T., Gaspar, M. M., O'Rourke, C. J., Lewinska, M., Andersen, J. B., Arretxe, E., Alonso, C., Santos-Laso, Á., Izquierdo-Sanchez, L., Jimenez-Agüero, R., Eizaguirre, E., Bujanda, L., Pareja, M. J., Prip-Buus, C., Banales, J. M., Rodrigues, C. M. P., & Castro, R. E. (2023). miR ‐21‐5p promotes NASH ‐related hepatocarcinogenesis. Liver International. https://doi.org/10.1111/liv.15682
Vancouver
Rodrigues PM, Afonso MB, Simão AL, Islam T, Gaspar MM, O'Rourke CJ, et al. miR ‐21‐5p promotes NASH ‐related hepatocarcinogenesis. Liver International. 2023. doi:10.1111/liv.15682
BibTeX
@article{Rodrigues2023,
author = {Rodrigues, Pedro M and Afonso, Marta B and Simão, André L and Islam, Tawhidul and Gaspar, Maria M and O'Rourke, Colm J and Lewinska, Monika and Andersen, Jesper B and Arretxe, Enara and Alonso, Cristina and Santos-Laso, Álvaro and Izquierdo-Sanchez, Laura and Jimenez-Agüero, Raúl and Eizaguirre, Emma and Bujanda, Luis and Pareja, Maria J and Prip-Buus, Carina and Banales, Jesus M and Rodrigues, Cecília M P and Castro, Rui E},
title = {miR ‐21‐5p promotes NASH ‐related hepatocarcinogenesis},
journal = {Liver International},
year = {2023},
doi = {10.1111/liv.15682}
}
EUVIMED